Literature DB >> 25213406

Maximal immune response and cross protection by influenza virus nucleoprotein derived from E. coli using an optimized formulation.

Wenling Wang1, Baoying Huang1, Tao Jiang1, Xiuping Wang1, Xiangrong Qi1, Wenjie Tan1, Li Ruan2.   

Abstract

The highly conserved internal nucleoprotein (NP) is a promising antigen to develop a universal influenza A virus vaccine. In this study, mice were injected intramuscularly with Escherichia coli-derived NP protein alone or in combination with adjuvant alum (Al(OH)3), CpG or both. The results showed that the NP protein formulated with adjuvant was effective in inducing a protective immune response. Additionally, the adjuvant efficacy of Al(OH)3 was stronger than that of CpG. Optimal immune responses were observed in BALB/c mice immunized with a combination of NP protein plus Al(OH)3 and CpG. These mice also showed maximal resistance following challenge with influenza A virus PR8 strain. Most importantly, 10 µg NP formulated with Al(OH)3 and CpG induced higher protection than did 90 µg NP. These findings indicated that a combination of Al(OH)3 and CpG may be an efficient adjuvant in the NP formulation.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Al(OH)(3); CpG; Influenza A virus; Nucleoprotein; Protective immunity; Protein subunit vaccines

Mesh:

Substances:

Year:  2014        PMID: 25213406     DOI: 10.1016/j.virol.2014.08.008

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  5 in total

1.  Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.

Authors:  Wenling Wang; Renqing Li; Yao Deng; Ning Lu; Hong Chen; Xin Meng; Wen Wang; Xiuping Wang; Kexia Yan; Xiangrong Qi; Xiangmin Zhang; Wei Xin; Zhenhua Lu; Xueren Li; Tao Bian; Yingying Gao; Wenjie Tan; Li Ruan
Journal:  Clin Vaccine Immunol       Date:  2015-04-01

2.  Expression of H3N2 nucleoprotein in maize seeds and immunogenicity in mice.

Authors:  Hartinio N Nahampun; Brad Bosworth; Joan Cunnick; Mark Mogler; Kan Wang
Journal:  Plant Cell Rep       Date:  2015-02-13       Impact factor: 4.570

3.  Development of the H3N2 influenza microneedle vaccine for cross-protection against antigenic variants.

Authors:  Yura Shin; Jeonghun Kim; Jong Hyeon Seok; Heedo Park; Hye-Ran Cha; Si Hwan Ko; Jae Myun Lee; Man-Seong Park; Jung-Hwan Park
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

4.  Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.

Authors:  Wenling Wang; Baoying Huang; Xiuping Wang; Wenjie Tan; Li Ruan
Journal:  Virol Sin       Date:  2019-06-25       Impact factor: 4.327

Review 5.  Selecting and Using the Appropriate Influenza Vaccine for Each Individual.

Authors:  Toshiki Sekiya; Marumi Ohno; Naoki Nomura; Chimuka Handabile; Masashi Shingai; David C Jackson; Lorena E Brown; Hiroshi Kida
Journal:  Viruses       Date:  2021-05-24       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.